Unique ID issued by UMIN | UMIN000053317 |
---|---|
Receipt number | R000060857 |
Scientific Title | A phase II study to evaluate the safety of first-time radical gastrectomy by robotic approach for stomach cancer in an early stage |
Date of disclosure of the study information | 2024/01/10 |
Last modified on | 2024/01/10 23:04:04 |
A phase II study to evaluate the safety of first-time radical gastrectomy by robotic approach for stomach cancer in an early stage
ERSTE-M study
A phase II study to evaluate the safety of first-time radical gastrectomy by robotic approach for stomach cancer in an early stage
ERSTE-M study
Japan |
Gastric cancer
Gastrointestinal surgery |
Malignancy
NO
To evaluate the safety of robotic distal gastrectomy (RDG) with lymph node dissection performed by surgeons with limited experience in gastric cancer surgery
Safety
Incidence of intra-abdominal infectious complications after gastrectomy
1. overall survival, 2. relapse-free survival, 3. completion rate of robotic surgeries, 4. incidence of adverse events
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Maneuver |
Robotic distal gastrectomy (RDG) with lymph node dissection of D1+ or higher, performed under proctor guidance via dual console by surgeons with limited experience performing gastric cancer surgery
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically proven gastric adenocarcinoma by endoscopic biopsy.
2) The diagnosis of clinical T1N0.
3) Not indicated for ESD.
4) Distal or total gastrectomy is required for radical resection, and R0 surgery is feasible.
5) No invasion to duodenum.
6) Aged 20 years old or older.
7) Eastern Cooperative Oncology Group performance status of 0 or 1.
8) Body mass index (BMI) is less than 30.
9) No history of upper abdominal surgery except laparoscopic cholecystectomy.
10) No prior chemotherapy, endocrine therapy and/or radiotherapy for any malignancies.
11) Adequate organ functions defined as;
i) WBC of 3,000/mm3 or more
ii) Platelet count 100,000/mm3 or more
iii) AST and/or ALT of 100 IU/L or less
iv) T.Bil of 2.0 mg/dL or less
v) Creatinine of 1.5 mg/dL or less
12) Written informed consent.
1) Synchronous or metachronous (within 5 years) malignancies.
2) During pregnancy, within 28 days postpartum, or during lactation.
3) Severe mental disease.
4) Receiving continuous systemic corticosteroid or immunosuppressant treatment.
5) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration.
6) Poorly controlled hypertension.
7) Uncontrolled diabetes mellitus.
8) Respiratory disease requiring continuous oxygen administration.
22
1st name | Makoto |
Middle name | |
Last name | Hikage |
Iwate Prefectural Isawa Hospital
Division of Surgery
023-0864
61 Ryugababa, Mizusawa-ku, Oshu-shi, Iwate, Japan
0197-24-4121
mhikage@med.tohoku.ac.jp
1st name | Makoto |
Middle name | |
Last name | Hikage |
Iwate Prefectural Isawa Hospital
Division of Surgery
023-0864
61 Ryugababa, Mizusawa-ku, Oshu-shi, Iwate, Japan
0197-24-4121
mhikage@med.tohoku.ac.jp
Iwate Prefectural Isawa Hospital
self-funding
Self funding
Iwate Prefectural Isawa Hospital Institutional Review Board
61 Ryugababa, Mizusawa-ku, Oshu-shi, Iwate, Japan
0197-24-4121
isawasenmoni@gmail.com
NO
2024 | Year | 01 | Month | 10 | Day |
Unpublished
Enrolling by invitation
2023 | Year | 08 | Month | 10 | Day |
2023 | Year | 08 | Month | 16 | Day |
2024 | Year | 01 | Month | 10 | Day |
2031 | Year | 07 | Month | 31 | Day |
2024 | Year | 01 | Month | 10 | Day |
2024 | Year | 01 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060857